Aiforia and Orion, a Finnish pharmaceutical company, have announced the extension of their collaboration to include the use of Aiforia's software solution for preclinical study evaluations.
This collaboration involves implementing the AiforiaStudies module within Orion's preclinical histology processes, as well as joint development to further automate and improve the study evaluation workflow of preclinical pathologists.
“We are extremely pleased to expand our collaboration with Orion. The AiforiaStudies module is specifically designed for the needs of the pharmaceutical industry and their preclinical histology studies. It is exciting to collaborate with this innovative pharmaceutical company to gain valuable insights into their requirements and further develop our offering for this sector. Through this collaboration, we will strengthen our preclinical portfolio that already spans from the discovery phase to safety studies, seamlessly integrating with our AI-based image analysis tools,” says Jukka Tapaninen, CEO of Aiforia.
“We are thrilled to deepen our partnership with Aiforia; the AiforiaStudies module aligns perfectly with our commitment to advancing pharmaceutical research and development. By leveraging Aiforia's AI-based image analysis and reporting tools, we expect faster and more efficient pathological evaluations, reducing the time required from pathologists to assess sample slides and improving the accuracy of our preclinical studies. We look forward to the valuable insights and advancements this partnership will bring”, says Riikka Oksala, Director, DMPK & Safety Sciences, R&D, Orion.
To learn more about AiforiaStudies, visit https://www.aiforia.com/aiforia-research-solutions.